HIVNCT02677675
Effectiveness of Mobile Phone Technology on Adherence and Treatment Outcomes Among HIV Positive Patients on ART
A study testing Intervention (reminder module) in people with HIV, run by Universiti Putra Malaysia.
Trial summary
The objective of this study was to determine the effectiveness of mobile phone technology (SMS and telephone call reminders) in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia. Read more about this study
- Who is it for?
- Ages 15 to 65 years
- Conditions the study is for
- HIV
- What is being tested?
- Intervention (reminder module)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 242 participants
- Where
- No sites listed yet
- Study dates
- Jan 2014to Dec 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- All HIV positive patients aged 15 - 65 years, assessed and eligible for ART commencement.
- All ART eligible patients who have valid telephone numbers and can read text messages.
Who cannot join
- All HIV positive patients already commenced (current) or restarting ART due to previous default and/or lost-to-follow-up status
- Pregnant HIV-positive ART patients
- Foreigners
About this study
Official title: Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia
The objective of this study was to determine the effectiveness of mobile phone technology (SMS and telephone call reminders) in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia.
Read the detailed description
This study was a 2 arm, parallel group, randomized single blind clinical trial involving 242 randomly selected and allocated adult Malaysian HIV positive patients who were enrolled into Antiretroviral Therapy (ART) care at Infectious Disease Clinic of Hospital Sungai Buloh, Malaysia. Recruitment commenced in January 2014 and follow up ended in December 2014. Each individual patient was followed up for a period of 6 months on ART. A reminder module (delivered via Short Message Service (SMS) and telephone call reminders) was developed based on the Theory of Planned Behavior. The reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants) while respondents in the control group received standard care only. Each patient in the intervention group had a minimum of three (during clinic visits at month 1, month 3 and month 6) individual counselling sessions with the research assistants lasting an average of 15 minutes per encounter. To ensure confidentiality, typical medication reminder text messages included a short slogan in Malay language "Apa khabar" "Ini untuk menberithau anda ubat" meaning "How are you?" "This is to remind you of your medications". Appointment reminder text message was "Apa khabar" "Tolong ingat tarikh temu janji lusa" meaning "How are you?" "Remember your appointment day after tomorrow" and telephone conversation was standardized and short, with the message "Apa khabar" "Tolong ingat tarikh temu janji besok" meaning "How are you?" "Remember your appointment tomorrow". Patients were not required to provide any responses to the text messages. However, a log of text message communications and telephone calls was recorded and kept.
Upon enrollment and randomization to a treatment arm, baseline data on socio-demographic factors, clinical symptoms and adherence behavior of respondents was collected using modified, pre-validated, reliable, self-administered Adult AIDS Clinical Trial Group (AACTG) adherence questionnaire. The baseline medication adherence questionnaire consisting of nine sections was used to collect data on patient's understanding and level of preparedness to take HIV medications, level of psychosocial support from their friends and families, reasons for missing medications as well as period and number of missed medications. Other information collected were on patient's psychosocial symptoms and well-being, history of drug and alcohol use, socio-demographic characteristics, source of HIV infection and disclosure status, and review of their symptoms in the past 30 days. Responses to questions in sections A - E1 were graded on a 4-point Likert scale, sections E2 and I on a 5-point Likert scale, section F on a multiple scale (multiple choice, 2-point and 4-point scales), H on a 2-point scale, while section G had 5 questions on socioeconomic and demographic characteristics.
Baseline weight, blood pressure, CD4 count, Viral load, as well as results of renal profile and liver function tests were also collected and recorded.
Adherence measurement was repeated at 3 and 6 months follow-up using self-administered AACTG follow-up adherence questionnaires which consisted of eight sections (sections A - H) and a total of 49 questions graded on a combination of Likert and "Yes" or "No" scales, used for assessing how well the patient has adhered to their medications and specific instructions about their regimen within the past 3 months, with particular emphasis on the past four days. It also contained a review of their symptoms during the past four weeks as well as their current TB status and OI index. Section A consisted of a review of the respondent's current medications, by evaluating their understanding and knowledge of the treatment regimen in terms of drug name, frequency and strength of dosage, how long the patient has been on the regimen, number of pills per dose as well as number of doses missed in the past four days. This section was completed in a collaborative manner between the study personnel and the patient. Responses to questions in sections B, C, D \& H were graded on a 5-point Likert scale, E on a 2-point scale, F on a 6-point scale, and G on a 4-point scale.
CD4 count, viral load, weight, full blood count, liver function, renal profile and blood pressure measurements were repeated at 6 months follow-up period, and the results retrieved from laboratory records.
Adherence scores were calculated using a standardized adherence index formula adopted from Reynolds et al.(2007). Data on regularity of respondents' scheduled clinic visits was obtained by the research assistants (for whom access was duly sought and provided by the hospital management) from the hospital's electronic medical records system using standardized data extraction forms and corroborated with drug refill appointments from pharmacy records. The research assistants accessed and recorded onto the data extraction forms, information on patient's TB status, opportunistic infection (OI) index and body weight from clinicians' notes in the electronic medical record system. Data extraction forms were reviewed periodically for completeness, correctness and accuracy by the site study coordinator.
- Conditions
- HIV
- Being tested
- Intervention (reminder module)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention (reminder module)Behavioural
Reminder module (delivered via SMS and telephone call reminders)
| Study group | Role | What they receive |
|---|---|---|
| Intervention (reminder module) | Experimental | A "reminder module" which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants) Receives: Behavioral: Intervention (reminder module) |
| Control (standard care) | No intervention | Control group received standard care only (routine adherence counselling and paper-based appointment scheduling) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence (improved scheduled clinic attendance and medication adherence self-report)
Medication adherence was measured based on adherence ratio (for each of the 4 days prior was calculated as 1 minus (number of doses missed for the day/number of doses prescribed); adherence index based on formula adapted from Reynolds et al, 2007; and adherence category (>95% = Good adherence; 80-95% = Fair adherence; and <80% = Poor adherence) (WHO 2005).
Scheduled clinic attendance was measured and categorized based on the number of scheduled clinic visits attended, number of times defaulted and whether or not the patient was lost-to-follow-up
(a) Regular clinic attendee - a person who has never missed any scheduled clinic appointment (b) Defaulter - a person who has missed one or more scheduled clinic appointment, for any reason(s) (c) Lost-to-follow-up - a person is said to be lost to follow up if s/he refuses to show up for scheduled clinic visit for 3 consecutive months, after 3 consecutive attempts to track the client and bring them back on treatment.
Measured: Change from baseline adherence at 3 months and at 6 months
Secondary outcomes (5)
Immunological (improved CD4 count)
cells per millimeter cube of blood
Measured: Change from baseline CD4 count at 6 months
Virological (decreased viral load)
absolute counts and log10 values. Viral suppression: (a) All clients with viral load <400 copies/mL at 6 months were termed to have achieved viral suppression, and (b) viral load >400 copies/mL at 6 months was termed unsuppressed viral load.
Measured: Change from baseline viral load at 6 months
Clinical (Improved weight)
weight in Kg
Measured: Change from baseline weight at 6months
Clinical (TB status)
TB status: (a) No signs and symptoms of TB (b) TB suspected clinically and referred for evaluation (c) Currently on INH Prophylaxis (IPT) (d) Currently on TB treatment. This was extracted onto the AACTG questionnaires from clinician's records based on clinical evaluation during hospital visits. Patient's susceptibility to, or recovery from TB was expected to correlate with immune status/recovery
Measured: Change from baseline TB status at 6 months
Clinical (Opportunistic infection index)
OI index: (a) WHO Clinical Stage 1 (b) WHO Clinical Stage 2 (c) WHO Clinical Stage 3 (d) WHO Clinical Stage 4. This was extracted onto the AACTG questionnaires from clinician's records based on clinical evaluation during hospital visits. Patient's susceptibility to, or recovery from OIs was expected to correlate with immune status/recovery
Measured: Change from baseline Opportunistic Infection (OI) index at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2016 (estimated)
- Study startJan 2014
- Primary completionDec 2014
- Study completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 242 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universiti Putra Malaysia
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of Health, Malaysia
- Responsible party
- Principal investigator, Dr. Surajudeen Abiola Abdulrahman, Universiti Putra Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02677675
- Sponsor's protocol ID
- UPM/TNCPI/RMC/1.4.18.1 (JKEUPM
- Status last verified
- Feb 2016
- First submitted
- 2 Feb 2016
- Last updated
- 9 Feb 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia
- ClinicalTrials.gov ID
- NCT02677675
- Acronym / sponsor ID
- UPM/TNCPI/RMC/1.4.18.1 (JKEUPM
- Conditions
- HIV
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 242 participants (actual)
- Lead sponsor
- Universiti Putra MalaysiaUniversity, hospital or other
- Collaborators
- Ministry of Health, Malaysia
- Study start
- Jan 2014
- Primary completion
- Dec 2014 (actual)
- Study completion
- Dec 2014 (actual)
- First posted
- 9 Feb 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study was to determine the effectiveness of mobile phone technology (SMS and telephone call reminders) in improving adherence and treatment outcomes among HIV positive patients on ART in Malaysia.
Detailed description
This study was a 2 arm, parallel group, randomized single blind clinical trial involving 242 randomly selected and allocated adult Malaysian HIV positive patients who were enrolled into Antiretroviral Therapy (ART) care at Infectious Disease Clinic of Hospital Sungai Buloh, Malaysia. Recruitment commenced in January 2014 and follow up ended in December 2014. Each individual patient was followed up for a period of 6 months on ART. A reminder module (delivered via Short Message Service (SMS) and telephone call reminders) was developed based on the Theory of Planned Behavior. The reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants) while respondents in the control group received standard care only. Each patient in the intervention group had a minimum of three (during clinic visits at month 1, month 3 and month 6) individual counselling sessions with the research assistants lasting an average of 15 minutes per encounter. To ensure confidentiality, typical medication reminder text messages included a short slogan in Malay language "Apa khabar" "Ini untuk menberithau anda ubat" meaning "How are you?" "This is to remind you of your medications". Appointment reminder text message was "Apa khabar" "Tolong ingat tarikh temu janji lusa" meaning "How are you?" "Remember your appointment day after tomorrow" and telephone conversation was standardized and short, with the message "Apa khabar" "Tolong ingat tarikh temu janji besok" meaning "How are you?" "Remember your appointment tomorrow". Patients were not required to provide any responses to the text messages. However, a log of text message communications and telephone calls was recorded and kept.
Upon enrollment and randomization to a treatment arm, baseline data on socio-demographic factors, clinical symptoms and adherence behavior of respondents was collected using modified, pre-validated, reliable, self-administered Adult AIDS Clinical Trial Group (AACTG) adherence questionnaire. The baseline medication adherence questionnaire consisting of nine sections was used to collect data on patient's understanding and level of preparedness to take HIV medications, level of psychosocial support from their friends and families, reasons for missing medications as well as period and number of missed medications. Other information collected were on patient's psychosocial symptoms and well-being, history of drug and alcohol use, socio-demographic characteristics, source of HIV infection and disclosure status, and review of their symptoms in the past 30 days. Responses to questions in sections A - E1 were graded on a 4-point Likert scale, sections E2 and I on a 5-point Likert scale, section F on a multiple scale (multiple choice, 2-point and 4-point scales), H on a 2-point scale, while section G had 5 questions on socioeconomic and demographic characteristics.
Baseline weight, blood pressure, CD4 count, Viral load, as well as results of renal profile and liver function tests were also collected and recorded.
Adherence measurement was repeated at 3 and 6 months follow-up using self-administered AACTG follow-up adherence questionnaires which consisted of eight sections (sections A - H) and a total of 49 questions graded on a combination of Likert and "Yes" or "No" scales, used for assessing how well the patient has adhered to their medications and specific instructions about their regimen within the past 3 months, with particular emphasis on the past four days. It also contained a review of their symptoms during the past four weeks as well as their current TB status and OI index. Section A consisted of a review of the respondent's current medications, by evaluating their understanding and knowledge of the treatment regimen in terms of drug name, frequency and strength of dosage, how long the patient has been on the regimen, number of pills per dose as well as number of doses missed in the past four days. This section was completed in a collaborative manner between the study personnel and the patient. Responses to questions in sections B, C, D \& H were graded on a 5-point Likert scale, E on a 2-point scale, F on a 6-point scale, and G on a 4-point scale.
CD4 count, viral load, weight, full blood count, liver function, renal profile and blood pressure measurements were repeated at 6 months follow-up period, and the results retrieved from laboratory records.
Adherence scores were calculated using a standardized adherence index formula adopted from Reynolds et al.(2007). Data on regularity of respondents' scheduled clinic visits was obtained by the research assistants (for whom access was duly sought and provided by the hospital management) from the hospital's electronic medical records system using standardized data extraction forms and corroborated with drug refill appointments from pharmacy records. The research assistants accessed and recorded onto the data extraction forms, information on patient's TB status, opportunistic infection (OI) index and body weight from clinicians' notes in the electronic medical record system. Data extraction forms were reviewed periodically for completeness, correctness and accuracy by the site study coordinator.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention (reminder module) | Experimental | Behavioral: Intervention (reminder module)A "reminder module" which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants) |
| Control (standard care) | No intervention | –Control group received standard care only (routine adherence counselling and paper-based appointment scheduling) |
Who may qualify
- Ages
- 15 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- All HIV positive patients aged 15 - 65 years, assessed and eligible for ART commencement.
- All ART eligible patients who have valid telephone numbers and can read text messages.
Key exclusion criteria (3 listed)
- All HIV positive patients already commenced (current) or restarting ART due to previous default and/or lost-to-follow-up status
- Pregnant HIV-positive ART patients
- Foreigners
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intervention (reminder module)Reminder module (delivered via SMS and telephone call reminders) | Behavioural | Intervention (reminder module) |
Primary outcome
Adherence (improved scheduled clinic attendance and medication adherence self-report)
Time frame: Change from baseline adherence at 3 months and at 6 months
Medication adherence was measured based on adherence ratio (for each of the 4 days prior was calculated as 1 minus (number of doses missed for the day/number of doses prescribed); adherence index based on formula adapted from Reynolds et al, 2007; and adherence category (>95% = Good adherence; 80-95% = Fair adherence; and <80% = Poor adherence) (WHO 2005). Scheduled clinic attendance was measured and categorized based on the number of scheduled clinic visits attended, number of times defaulted and whether or not the patient was lost-to-follow-up (a) Regular clinic attendee - a person who has never missed any scheduled clinic appointment (b) Defaulter - a person who has missed one or more scheduled clinic appointment, for any reason(s) (c) Lost-to-follow-up - a person is said to be lost to follow up if s/he refuses to show up for scheduled clinic visit for 3 consecutive months, after 3 consecutive attempts to track the client and bring them back on treatment.
5 secondary outcomes
Immunological (improved CD4 count)
Time frame: Change from baseline CD4 count at 6 months
Virological (decreased viral load)
Time frame: Change from baseline viral load at 6 months
Clinical (Improved weight)
Time frame: Change from baseline weight at 6months
Clinical (TB status)
Time frame: Change from baseline TB status at 6 months
Clinical (Opportunistic infection index)
Time frame: Change from baseline Opportunistic Infection (OI) index at 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2016.
- Individual participant dataSharing planned: Undecided
Related trials for HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention (reminder module) in people with HIV, run by Universiti Putra Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adherence (improved scheduled clinic attendance and medication adherence self-report) (time frame: Change from baseline adherence at 3 months and at 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2016.